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Inhibition of JAK2 Signaling by TG101209 Enhances
Radiotherapy in Lung Cancer Models
Yunguang Sun, PhD,* Luigi Moretti, MD,* Nicholas J. Giacalone, BS,* Stephen Schleicher, BS,*
Christina K. Speirs, PhD,* David P. Carbone, MD, PhD,† and Bo Lu, MD, PhD*
Introduction: Persistent STAT3 activation contributes to lung car-
cinogenesis. Survivin, one of STAT3-regulated genes, is antiapop-
totic and confers cancer radioresistance.
Methods:We tested whether TG101209, a small-molecule inhibitor
of JAK2 (a STAT3-activating tyrosine kinase), affected survivin
expression and sensitized lung cancer to radiation. We investigated
whether inhibition of JAK2 signaling with TG101209 can be used to
reduce survivin expression and enhance radiosensitivity of lung
cancer cells in vitro and tumor growth delay in vivo. JAK2 down-
stream signaling, including PI3-K/Akt and Ras/MAPK/ERK path-
ways, was also explored.
Results: TG101209 inhibited STAT3 activation and survivin ex-
pression and sensitized HCC2429 (dose enhancement ratio  1.34,
p  0.002) and H460 (dose enhancement ratio  1.09, p  0.006)
cells to radiation in clonogenic assays. Radiation promoted phospho-
Akt and phospho-ERK in H460 cells, while their levels were
unchanged in HCC2429. After treatment with TG101209, phospho-
ERK protein levels were reduced in both HCC2429 and H460 cells.
HCC2429 cells transfected with KRAS-12V mutant were more
resistant to radiation- and TG101209-induced apoptosis than wild-
type control cells. In vivo, addition of TG101209 to radiation in lung
xenografts produced a significant tumor growth delay (10 days)
compared with radiation alone and was well tolerated. Immunohis-
tochemistry staining of tumor sections showed that TG101209
increased apoptosis and decreased cell proliferation and vascular
density, suggesting that TG101209 also has antiangiogenic effects.
Conclusions: TG101209 enhanced the effects of radiation in lung
cancer in vitro and in vivo. This study suggests the potential utility
of selecting lung cancer patients according to KRAS mutation status
for future clinical trials testing combination of TG101209 and
radiotherapy.
Key Words: Survivin, JAK2, Non-small cell lung carcinoma,
Radiation.
(J Thorac Oncol. 2011;6: 699–706)
Lung cancer is the leading cause of cancer mortality in2009,1 despite advances in therapy. Radiotherapy plays an
important role in lung cancer treatment, but the effectiveness
of this modality is often limited by defects in cell death
pathways. Research of novel sensitizing agents has focused
on cancer-specific targets to enhance radiation therapy by
making cancer cells more susceptible to death after radiation-
induced damage. One target that was explored is survivin, the
smallest member of the inhibitor of apoptosis protein family,
mainly because survivin is differentially expressed in tumors
compared with normal tissues.2 Indeed, it is overexpressed in
most cancers, including lung, and is therefore deemed an
attractive anticancer target either through inactivating the
survivin protein or by stopping the production of survivin
through inhibition of survivin gene expression. Accordingly,
we and others have found that survivin prevents apoptosis
and mediates resistance to radiation3–6 and has some prog-
nostic value for cancer patients, notably as an independent
biomarker for disease recurrence and overall survival in
patients with resected stage I/II non-small cell lung cancer
(NSCLC).7,8
Recently, studies have shown that one possible mech-
anism for the aberrant expression of survivin in cancer cells
may result from activation of transcription factors to maintain
survivin production.9 Accordingly, survivin has been identi-
fied as a direct target of the signal transduction and activator
of transcription-3 (STAT3), a member of a family of latent
cytosolic transcription factors, in primary effusion lymph-
oma9 and breast cancer.10 Activation of STAT3 supports cell
survival in association with survivin expression in gastric,11
breast, and prostate cancer cells.12 A strong association be-
tween STAT3 activation and survivin expression was found
in cancer tissues.13,14 We confirmed this relationship in our
previous study where we found that the use of a dominant-
negative mutant of STAT3 reduced survivin transcription and
subsequently sensitized breast cancer cells to radiation.15
STAT3 is activated by phosphorylation of a conserved ty-
rosine residue (Tyr705) by kinases such as Janus kinase 2
(JAK2) in response to cytokine stimulation,16 subsequently
promoting the dimerization of STAT3 monomers to render
*Department of Radiation Oncology and †Division of Hematology and
Medical Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt Uni-
versity, Nashville, Tennessee.
Disclosure: Tha authors declare no conflicts of interest.
Address for correspondence: Bo Lu, MD, PhD, Department of Radiation
Oncology, Vanderbilt University, 1301 22nd Avenue South, B-902 TVC,
Nashville, TN 37232-5671. E-mail: bo.lu@vanderbilt.edu
The first two authors contributed equally to this work.
Copyright © 2011 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/11/0604-0699
Journal of Thoracic Oncology • Volume 6, Number 4, April 2011 699
them in a transcriptionally active conformation. STAT3 then
translocates to the nucleus and binds to the promoter region
of target genes and activates their transcription.17,18 While
STAT3 activation is temporary in normal conditions, STAT3
is constitutively activated in many cancers and is commonly
associated with a worse prognosis.19,20 Persistent activation
of the JAK2/STAT3 signaling pathway contributes to carci-
nogenesis by promoting cell proliferation, metastasis, angio-
genesis, and resistance to apoptosis. In this study, we exam-
ined whether TG101209, a new small-molecule inhibitor of
JAK2, affected survivin expression in lung cancer and its
potential as a novel radiosensitizing agent for lung cancer.
MATERIALS AND METHODS
Cell Culture and Chemicals
H460 (America Type Culture Collection, Rockville,
MD) and HCC2429 (kindly provided by Dr. Tao Dang21)
lung cancer cells were cultured in RPMI 1640 containing
10% fetal bovine serum and 1% penicillin-streptomycin (In-
vitrogen, Carlsbad, CA). Cells were incubated at 37°C in a
humidified cell culture chamber with 5% CO2. Since the
American Type Culture Collection performs DNA profiling
of cell lines and as all cells were cultured for less than 6
months before being reconstituted from frozen stocks, no
additional authenticationwas done. Cellsweremaintained asmono-
layer cultures at 37°C in a humidified atmosphere of 5% CO2.
TG101209 was obtained from TargeGen (Cambridge, MA).
Immunobloting
Cells were washed twice with ice-cold phosphate-buff-
ered saline and lysed in M-Per mammalian lysis buffer
(Thermo Scientific, Rockford, IL). The protein concentration
of lysates was determined with the Bradford reagent (Bio-
Rad, Hercules, CA), and equal amounts of protein were
subjected to sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis of 10% or 15% gel. Separated proteins were
transferred to a nitrocellulose membrane, which was exposed
to 5% nonfat dry milk in 0.1% tris-buffered saline and Tween
20 for 1 hour at room temperature before incubation over-
night at 4°C with rabbit polyclonal antibodies to human
survivin (1:2000 dilution; R&D Systems, Minneapolis, MN),
human STAT3 and phospho-STAT3 (1:1000 dilution; Cell
Signaling, Danvers, MA), Caspase 3 (1:1000 dilution; Cell
Signaling), ERK and phospho-ERK (1:1000 dilution, Santa
Cruz Biotechnology, Santa Cruz, CA), Akt and phospho-Akt
(1:1000 dilution; Cell signaling), hemagglutinin (1:2000 di-
lution; Roche Applied Science, Indianapolis, IN), and actin
(1:8000 dilution; Sigma, St. Louis, MO). The membrane was
washed with Tris-buffered saline containing 0.1% Tween-20
before incubation for 1 hour at room temperature with horse-
radish peroxidase-conjugated goat antibodies to rabbit (Santa
Cruz Biotechnology). Immune complexes were detected with
chemiluminescence reagents (Perkin-Elmer Life Science).
Plasmids and Transfections
pCGN and pCGN-HA-KRAS-G12V were kindly pro-
vided by Dr. William Pao. HCC2429 cells were transfected
24 hours after being seeded in six-well plates. Plasmids (1.5
g) in 100 l of serum-free, antibiotic-free opt-MEM (Invit-
rogen) were mixed with 5 l Lipofectamine 2000 transfection
reagent (Invitrogen) dissolved in 100 l of the same medium
and allowed to stand at room temperature for 20 minutes. The
resulting 200 l transfection solutions were added to each
well containing 2 ml medium. Six hours later, the cultures
were replaced with 2 ml fresh medium supplemented with
10% fetal bovine serum and antibiotics. For Western blot,
cells were collected after an additional 48 hours. Drug or
radiation treatment was performed 24 hours after tranfection,
and cells were collected at indicated time.
In Vitro Clonogenic Assays
Exponentially growing cells were harvested by expo-
sure to trypsin and plated in triplicate in 60-mm dishes
containing 5 ml of complete medium in the presence of 1 M
TG101209 or vehicle (final DMSO concentration of 0.1%;
we confirmed that this DMSO concentration did not affect the
proliferation of NSCLC cell lines). After incubation for 2
hours, cells were irradiated using a 137Cs irradiator (J.L.
Shepherd and Associates). The dose rate was 1.8 Gy/min and
dose range was 0 to 6 Gy. Forty-eight hours after irradiation,
cells were washed with phosphate-buffered saline, cultured in
drug-free medium for 7 to 8 days, fixed with 70% ethanol,
and stained with 0.5% crystal violet (Sigma, St. Louis, MO).
Colonies containing more than 50 cells were counted. The
dose enhancement ratio (DER) was calculated as the dose
(Gy) of radiation that yielded a surviving fraction of 0.2 for
vehicle-treated cells divided by that for TG101209-treated
cells (after correction for drug toxicity).
Tumor Volume Assessment
HCC2429 lung cancer cells (1  106 cells in 100 l
DMEM) were injected subcutaneously into the right flank of
5- to 6-week-old female athymic nude (nu/nu) mice (Harlan
Sprague Dawley Inc., Indianapolis, IN) using a 1-ml syringe
with 271⁄2-gauge needle. Tumors were grown for 6 to 8 days
until average tumor volume reached 0.1 cm3. Treatment
groups consisted of vehicle control, TG101209, radiation,
and combined TG101209 with radiation. Each treatment
group contained five mice. TG101209 was administered
orally at doses of 100 mg/kg twice a day for 7 consecutive
days. Mice in radiation groups were irradiated 1 hour after
TG101209 treatment with 2 Gy daily over five consecutive
days. Tumors were irradiated using an x-ray irradiator
(Therapax, Agfa NDT, Inc., Lewis Town, PA) while nontu-
mor parts of mice were shielded by lead blocks. Tumors were
measured two or three times weekly in three perpendicular
dimensions using a Vernier caliper. Tumor volumes were
calculated using the modified ellipse volume formula (Vol-
ume  Height  Width  Depth/2). Tumor growth delay
was calculated as the number of days required to reach a
tumor volume of 0.4 cm3 for each treatment group relative to
control.
Histological Sections, von Willebrand Factor,
Ki-67, and Active Caspase-3
Mice were implanted with HCC2429 lung cancer cells
as described above in the tumor volume studies. After 6 to 8
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days, mice in the drug treatment group received an oral dose
of 100 mg/kg TG101209 twice a day for 7 days, with or
without radiation as described above in the tumor volume
studies. After 7 days of treatment, tumors from each mouse
were resected and fixed in paraffin. Slides from each treat-
ment group were stained for von Willebrand factor (vWF)
using anti-vWF polyclonal antibody (Chemicon, Billerica,
MA). Blood vessels were quantified by randomly selecting
400 fields and counting the number of blood vessels per
field. This was done in triplicate, and the average of the three
counts was calculated. Staining for Ki-67 (tumor prolifera-
tion) and active caspase-3 (apoptosis) was performed in the
Vanderbilt University Pathology Core laboratory using stan-
dard protocols. The number of positive cells per 400 field
were scored (by averaging multiple fields) and graphed by
averaging three repeated experiments.
Statistical Analysis
SE for all measured biological parameters is displayed
in the appropriate figures. Student t test was used to deter-
mine the significance between groups, using a statistical
package. Significance was defined at the level of p  0.05.
RESULTS
TG101209 Inhibits Survivin and Reduces
Phosphorylation of STAT3 in HCC2429 and
H460 Lung Cancer Cells
HCC2429 and H460 lung cancer cells were treated with
varying concentrations (0–3 M) of the JAK2 inhibitor
TG101209 for varying lengths of time (0–48 hours) to
determine the optimal treatment conditions that would affect
expression levels of total STAT3, phospho-STAT3, and sur-
vivin using Western blot analysis. Because the goal of the
study was to compare the response of the two cell lines to
TG101209, the treatment dose was calibrated based on the
more sensitive cell line, HCC2429. Therefore, 1 M was
chosen as the treatment dose, as the HCC2429 cell line could
not tolerate higher doses. Levels of apoptosis were assessed
by caspase-3 cleavage. As shown in Figure 1, 1 and 3 M
TG101209 reduced phospho-STAT3 in both cell lines while
total STAT3 remained constant throughout with only a minor
reduction after treatment with 3 M TG101209 for 48 hours.
We also demonstrate that 1 M of TG101209 is an adequate
dose to inhibit pSTAT3, as there was no increased inhibition
with 3 M of TG101209 at the 24-hour time point. Using
similar treatment conditions, 1 M TG101209 was able to
inhibit survivin expression at both 24 and 48 hours in
HCC2429 cells. In contrast, H460 cells required 3 M
TG101209 for 48 hours to significantly reduce survivin.
Finally, caspase-3 cleavage was observed in HCC2429 cells
treated with 3 M TG101209, particularly at 48 hours, but
was not detected in H460 cells using similar conditions.
TG101209 Results in Radiosensitization of
HCC2429 and H460 Lung Cancer Cells In Vitro
To investigate whether TG101209 radiosensitizes
HCC2429 and H460 lung cancer cells, clonogenic assays
were performed using 1 M TG101209 with varying doses of
radiation (0–6 Gy). Surviving colonies were quantified 8
days after irradiation to generate survival curves for both cell
lines (Figure 2). HCC2429 cells (Figure 2A) receiving
TG101209 had increased sensitivity to the lethal effect of
radiation, with a DER of 1.34 (p  0.002). Although statis-
tically significant, H460 cells (Figure 2B) only demonstrated
a slight increase in radiosensitivity, as indicated by a DER of
1.09 (p  0.006). These data suggest that lower doses of
radiation are required to achieve an equivalent antitumor
effect when TG101209 is combined with radiation compared
with radiation alone in vitro, particularly in HCC2429 lung
cancer cells.
Effects of Radiation and TG101209 on PI3K/
Akt and Ras/MAPK/ERK Pathways
Our finding that TG101209 has greater effects in
HCC2429 cells compared with H460 cells led us to investi-
gate downstream proteins that can be affected by JAK2,
including the phosphoinositide 3-kinase (PI3K)/Akt and the
Ras/mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) pathways. As shown in Figure
3A, radiation alone (6 Gy) promoted phospho-Akt and phos-
pho-ERK expression in H460 cells. However, phospho-Akt
levels were unchanged and phospho-ERK was only mini-
mally detected in irradiated HCC2429 cells. After treatment
with TG101209 (Figure 3B), phospho-ERK and phospho-Akt
protein levels were reduced by 30 minutes up to 4 hours in
H460 cells. This inhibition was not observed anymore at 24
hours. In HCC2429 cells, phospho-ERK protein levels were
FIGURE 1. TG101209 inhibits survivin and re-
duces phosphorylation of STAT3 in HCC2429 and
H460 lung cancer cells. HCC2429 and H460 cells
were treated with 1 or 3 M TG101209 for 24 or
48 hours. Shown are results of Western blots us-
ing labeled antibodies to phospho- and total
STAT3, survivin, pro-caspase-3, and cleaved
caspase-3. Actin was probed to demonstrate
equal loading.
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reduced by 30 minutes after treatment with TG101209 while
phospho-Akt was not affected. When HCC2429 and H460
cells were treated with a combination of radiation treatment
and TG101209, there was a synergistic inhibition of phospho-
ERK in treated H460 cells, whereas there was no significant
difference between HCC2429 cells that were treated with
combined treatment versus a single agent (data not shown).
Differential Effect of KRAS Mutation Status on
Radiation- and TG101209-Induced Apoptosis in
Lung Cancer Cells
To further investigate the differential resistance of
H460 cells to radiation-induced apoptosis compared with
HCC2429 cells, we investigated whether the presence of a
KRAS mutation in H460 cells (and not in HCC2429) could be
one potential factor that limits the induction of caspase
cleavage. We transfected HCC2429 cells that are wild-type
KRAS with a plasmid containing the KRAS G12V mutation
and tested caspase-3 cleavage by Western immunoblotting.
As shown in Figure 4A, HCC2429 cells transfected with
KRAS G12V mutation exhibited less apoptosis than
HCC2429 control cells, as evidenced by decreased levels of
cleaved caspase-3 after 1 or 3 M TG101209. Similarly, 6 or
10 Gy radiation induced less caspase-3 cleavage in HCC2429
cells with KRAS mutant as compared with HCC2429 vector
FIGURE 2. Radiosensitization of
HCC2429 and H460 lung cancer
cells by TG101209. HCC2429 (A) or
H460 (B) cells were treated with 1
M TG101209 or DMSO for 2
hours followed by irradiation with
the indicated doses. Forty-eight
hours after radiation, drug-contain-
ing media was replaced with fresh
media. After 8 days, surviving colo-
nies were stained and scored.
Shown are survival curves contain-
ing the mean  SD of three sepa-
rate, repeated experiments.
FIGURE 3. Effects of radiation and TG101209
on PI3K/Akt and Ras/MAPK/ERK pathways.
HCC2429 and H460 cells were treated with 6
Gy radiation (A) or 1 M TG101209 (B) for 30
minutes, 1, 2, 4, and 24 hours, or DMSO con-
trol. Shown are results of Western blots using
labeled antibodies to phospho- and total
STAT3, phospho- and total Akt, phospho- and
total ERK, and survivin. Actin was probed to
demonstrate equal loading.
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control cells (Figure 4B). This suggests diminished TG101209-
and radiation-induced apoptosis in the presence of mutated
KRAS. In addition, a comparison of the protein profile between
the KRAS HCC2429 mutant cells and wild-type HCC2429 cells
revealed that phospho-ERK levels are greater in KRAS-mutant
HCC2429 cells than in wild-type controls (Figure 4C).
Combination of TG101209 and Radiation
Extends Tumor Growth Delay and is Well
Tolerated In Vivo
To test whether the radiosensitizing effects of
TG101209 on lung cancer cells in vitro could be translated in
vivo, tumor growth was assessed in a mouse xenograft model
in which HCC2429 lung cancer cells were injected into
mouse hind limbs and treated as discussed in the Material and
Methods section. Tumor growth delay was calculated as the
number of days required to reach a tumor volume of 0.4 cm3
for treatment groups relative to control tumors. As shown in
Figure 5, tumor growth delay was significantly extended for
mice receiving combination therapy for TG101209 and radi-
ation compared with mice receiving radiation alone (16 days
versus 10 days, p  0.04). Notably, TG101209 treatment
without radiation also significantly prolonged tumor growth,
compared with no treatment (3 days delay, p  0.04).
The body weights of all mice were monitored to assess
the tolerability of systemic TG101209 therapy. As shown in
Supplemental Figure 1, body weight changes over the course
of the experiment were minimal in all treatment groups,
suggesting that TG101209 is well tolerated.
TG101209 Reduces Tumor Proliferation and
Vascular Density and Increases Apoptosis in
Irradiated Lung Cancer Mouse Xenografts
To determine the mechanism that contributes to tumor
growth delay extension after combination treatment in vivo,
Ki-67 proliferation index was examined using fixed tumor
sections to quantify cellular proliferation. As shown in Figure
6A, combined TG101209 and radiation treatment resulted in
an approximately four-fold reduction of proliferating cells
compared with control (30 cells versus 117 cells, p  0.001)
and a 50% reduction compared with radiation alone (30 cells
versus 46 cells, p  0.001). As tumor vasculature is an
important target for cancer therapy, we assessed vessel den-
sity in tumor sections by staining for vWF. As is shown in
Figure 6B, the average number of vessels per microscopic
field was lower for tumors treated with combination
TG101209 and radiation than in tumors receiving radiation
alone or control (3 vessels versus 5 vessels versus 15 vessels;
FIGURE 4. Radiation- and TG101209-induced
apoptosis is modulated by KRAS mutation status
in lung cancer cells. HCC2429 KRAS wild-type
cells were transfected with a plasmid containing
the KRAS G12V mutation and then were treated
with either DMSO control, 1 or 3 M TG101209
(A), or 0, 6, and 10 Gy radiation (B) for 24 and
48 hours. Shown are results of Western blots us-
ing labeled antibodies to pro-caspase-3, cleaved
caspase-3, and human influenza hemagglutinin
(HA). (C), Forty-eight hours after transfection,
untreated wild-type and KRAS-mutated HCC2429
cells were collected for Western blot and probed
with antibodies to phospho- and total STAT3,
phospho- and total ERK, phospho- and total Akt,
and survivin. Actin was probed to demonstrate
equal loading.
FIGURE 5. Combination of TG101209 and radia-
tion prolongs tumor growth delay in lung cancer
xenograft model. HCC2429 lung cancer cells (1 
106 cells in 100 l DMEM) were injected subcuta-
neously into athymic nude mice. After 6 to 8
days, mice were treated with vehicle control,
TG101209 (100 mg/kg twice a day for 7 consecu-
tive days), radiotherapy, or combined TG101209
and radiotherapy (mice were irradiated 1 hour
after TG101209 treatment with 2 Gy daily for 5
consecutive days). Tumor growth delay as defined
by the number of days required to reach a tumor
volume of 0.4 cm3 was measured. Tumors were
measured regularly and growth delay was calcu-
lated for treatment groups relative to control.
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p  0.001 for both comparisons). Finally, apoptosis was
assessed using active caspase-3 staining (Figure 6C). Because
lymphocytes expressing caspase-3 can invade tumor tissue,
we cannot exclude a subpopulation of caspase-3-expressing
lymphocytes, although we believe that the number of cells
would be small to negligible. Combined TG101209 and
radiation treatment resulted in 47 positive apoptotic cells,
compared with 20.7 in radiation alone (p  0.002) and 16.3
in control tumors (p  0.001). Representative photographs
for fixed tumor sections stained for cellular proliferation
(Ki-67), vasculature (vWF), and apoptosis (active caspase-3)
are presented in Supplemental Figure 2.
DISCUSSION
In this report, we demonstrate the radiosensitizing ef-
fects of TG101209, a novel small-molecule inhibitor of
JAK2, in lung cancer models. We found that TG101209 was
able to inhibit survivin, reduce phosphorylation of STAT3,
and sensitize lung cancer cells to radiation in vitro. In lung
cancer xenografts, the combination of TG101209 and radia-
tion extended tumor growth delay and was well tolerated.
Analyses of tumor sections from in vivo experiments showed
that TG101209 increased apoptosis while reducing tumor
proliferation and vascular density. Survivin expression is
notably absent in most terminally differentiated normal tis-
sues, in contrast to its high expression in a variety of cancers.2
Consistent with this observation, we detected high levels of
survivin in both HCC2429 and H460 lung cancer cells in the
absence of treatment (Figure 1). Of particular interest, levels
of survivin in lung cancer cells are among the highest found
in human tumors,22 and its expression was found to be an
independent biomarker for recurrence and survival in patients
with NSCLC.8 In addition, there is a growing body of
evidence suggesting that persistent expression of survivin has
an important role in radioresistance of malignant cells, likely
through decreased apoptosis, which has been found in several
tumor types, including colon,23 breast,24 and pancreas.25
These characteristics make survivin an attractive target for
cancer therapy and radiosensitization. We previously found
that overexpression of survivin leads to radiation resistance
by inhibiting apoptosis and promoting cell survival, and
survivin inhibition using antisense oligonucleotide enhanced
the cytotoxic effects of radiation in H460 lung cancer cells.6
In this study, we explored an alternative strategy to
target survivin in lung cancer, based on previous findings that
STAT3 regulates survivin transcription.10,26 This likely me-
diates radiation resistance in breast cancer cells, as targeting
phospho-STAT3 using a dominant-negative mutant subse-
quently sensitizes breast cancer cells to radiation.15 In addi-
tion to its major role in hematologic malignancies, STAT3 is
also activated in 55% of NSCLC tumors27 and in most
NSCLC cell lines in vitro,28 which was consistent with our
FIGURE 6. TG101209 with radiation reduces Ki-67 proliferative marker and blood vessel density and increases apoptosis in
lung tumor xenograft model. Histological sections were obtained from the tumors of the mice in each treatment group from
the tumor volume study. A, Staining for Ki-67 was performed to assess cell proliferation and the number of positive cells was
scored and graphed by averaging three repeated experiments. B, Slides were stained for von Willebrand factor (vWF) using
anti-vWF antibody to determine vessel density and the number of blood vessels per random 400 fields was scored and
graphed by averaging three repeated experiments. C, Staining for active caspase-3 was performed to measure apoptosis and
the number of positive cells was scored and graphed by averaging three repeated experiments; *p  0.05.
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results (Figures 1 and 3). Because adenoviral delivery of
dominant-negative proteins may have only limited applica-
tions for cancer therapy,28 we targeted STAT3-mediated
transcription of survivin using a small-molecule inhibitor of
JAK2, TG101209. Previous studies with TG101209 have
focused on myeloproliferative disorders, mainly because of
the primary role of JAK2 mutations such as V167F in those
diseases.29–32
In this study, we found that expression of survivin was
inhibited at 24 and 48 hours by 1 or 3 M TG101209 and was
positively associated with reduced level of phospho-STAT3
in HCC2429 cells (Figure 1). In contrast to HCC2429 cells,
we found the level of survivin to be only slightly reduced at
24 hours in H460 cells and more greatly inhibited at 48 hours
using 3 M TG101209 relative to control. This reduction in
survivin paralleled the decreased phospho-STAT3 for both
concentrations and time points. Similarly, there was a corre-
lation between promotion of caspase-3 cleavage and reduc-
tion of survivin levels at 24 hours in HCC2429 cells as
opposed to H460 cells, which displayed higher survivin
levels at both concentrations. Although a dose of 3 M
resulted in a significant decrease in survivin expression at 48
hours, there was no detectable cleaved caspase-3 in H460
cells, suggesting a more resistant apoptotic phenotype com-
pared with HCC2429 cells. These data mirrored the clono-
genic assay results (Figure 2) where HCC2429 cells were
more dramatically sensitized to radiation compared with
H460 cells. These findings are consistent with other studies
that show a correlation between the rate of apoptosis and
intrinsic radiosensitivities of lung carcinoma cells.33
One potential factor that might contribute to the en-
hanced resistance to apoptosis in H460 compared with
HCC2929 cells is the presence of a KRAS mutation found in
H460 but not in HCC2429 cells.34 To elucidate the role of this
KRAS mutation, we performed a KRAS 12V mutant transfec-
tion in HCC2429 cells and analyzed TG101209- and radia-
tion-induced caspase-3 cleavage. Interestingly, we found that
radiation-induced apoptosis was considerably lower in KRAS-
transfected HCC2429 cells versus wild-type controls, at both
24 and 48 hours (Figure 4B). Similarly, after TG101209
treatment (Figure 4A), we were not able to detect cleaved
caspase-3 at 24 hours in KRAS-mutant cells compared with
controls, and apoptosis was also reduced at 48 hours. Taken
together, these observations suggest that KRAS mutation
status is one potential factor associated with increased resis-
tance to either radiation- or TG101209-induced apoptosis in
lung cancer cells.
Another possible contributor to the increased radiation
resistance in H460 cells may be the Ras/MAPK/ERK path-
ways, which may regulate STAT3 phosphorylation through
cross-talk.35 As shown in Figure 3A, phospho-ERK levels
were higher in H460 cells than in HCC2429 cells, which
might have contributed to increased resistance to radiation as
activation of the ERK signaling pathway tends to be antiapo-
ptotic.36 Although radiation induces ERK activation in cells
without KRAS mutations,37 we found that phospho-ERK
levels were significantly promoted in KRAS-mutant
HCC2429 cells compared with vector control (Figure 4C),
which might induce inherent resistance to apoptosis and
subsequent resistance to treatment. Indeed, about 30% of lung
carcinomas contain activating KRAS mutations, which are
associated with resistance to various agents including endo-
thelial growth factor receptor tyrosine kinase inhibitors.36
In this in vivo study (Figure 6C), caspase-3 immuno-
staining was performed in tumor tissues. After radiation
treatment, there was a modest increase in active caspase-3
compared with control, confirming the relative resistance of
lung tumors to radiation-induced apoptosis. With the combi-
nation of TG101209 and radiation, apoptosis was further
increased compared with either radiation alone or drug alone,
in an additive manner. Moreover, TG101209, similar to
radiation alone, was able to significantly reduce tumor cell
proliferation compared with the control, while combination
of both did not result in an additive effect (Figure 6A).
However, the addition of TG101209 to radiation synergisti-
cally extended tumor growth delay compared with radiation
alone (Figure 5), suggesting the potential of TG101209 as a
radiation therapy enhancer in lung cancer.
In addition to its inhibitory role on JAK2, TG101209
has also been reported to inhibit JAK3, FLT3, and RET.32
Therefore, we cannot conclude with complete certainty that
JAK2 is wholly responsible for the radiosensitizing effect of
TG101209. Although a role for FLT3 in survivin expression
has not been described in lung cancer, one study has shown
that FLT3-mediated signaling regulates survivin expression
in acute myeloid leukemia.38 Vargiolu et al.39 have shown
that overexpression of RET inhibits a proapoptotic aryl hy-
drocarbon receptor-interacting protein (AIP)-survivin com-
plex. Thus, we assume that inhibition of RET would induce
an antiapoptotic state and not a proapoptotic state as we have
observed. Therefore, it is likely that any inhibition of RET by
TG101209 was insufficient to disrupt association of the
AIP-survivin complex. We are unaware of any publications
indicating a role for JAK3 in the regulation of survivin
expression. Taken together, our results indicate a strong role
for abrogation of JAK2 in the radiosensitization of NSCLC
with TG101209, although we cannot exclude downregulation
of other antiapoptotic pathways such as PI3K or Ras/MEK.
This preclinical study supports the therapeutic potential
of TG101209, a selective small-molecule inhibitor of JAK2,
as a radiosensitizer for lung cancer. These findings also
suggest that the effects of TG101209 involve the reduction of
survivin expression levels and induction of apoptosis. Bene-
ficial effects were confirmed in vivo where TG101209 plus
radiation caused prolonged tumor growth delay compared
with either radiation or drug alone. Further studies are needed
to determine the clinical therapeutic potential of TG101209 in
combination with radiotherapy for patients with NSCLC and
the value of KRAS mutation status as a predictive factor for
response to therapy and selection criteria.
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